The efficacy of artificial(nonbiological)extracorporeal liver support system for primary biliary cholangitis and the effect of this therapy on prognosis
10.3969/j.issn.1006-5725.2024.07.013
- VernacularTitle:非生物型人工肝支持系统治疗原发性胆汁性胆管炎患者的临床疗效及预后影响
- Author:
Futao DANG
1
;
Yingmei TANG
;
Haiyan FU
;
Huanlong LI
;
Jia-Min XU
;
Xu TAN
Author Information
1. 昆明医科大学第二附属医院消化内科(昆明 650021)
- Keywords:
primary biliary cholangitis;
artificial liver;
curative effect;
prognosis
- From:
The Journal of Practical Medicine
2024;40(7):955-961
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy of plasma exchange(PE)and double plasma molecular absorption system(DPMAS)in the treatment of primary biliary cholangitis(PBC)and the effect of this therapy on prognosis.Methods The clinical data on 526 PBC patients in our hospital from December 2013 to January 2022 were retrospectively analyzed.The patients were divided into different groups according to different therapies and then matched with propensity.The changes in symptoms,laboratory indexes and MELD scores were compared between two groups before and after treatment,and the clinical efficacy of artificial liver treatment for PBC patients was assessed.The effect of this treatment on the survival outcomes in these patients via comparing the cumulative survival rates at 3,6 and 12 months between the two groups.Results The efficiency was better in the group with artificial liver treatment in addition medical therapy than the group with medical treatment alone,the difference was statistically significant(76.7%vs.55.8%,χ2 = 4.214,and P = 0.040).Cox proportional risk regression showed that TBIL was an independent risk factor affecting the 3-,6-,or 12-month survival in PBC patients.Conclusions Artificial liver support system can effectively relieve symptoms,reduce levels of ALT,AST and TBIL,improve blood coagula-tion function,and lower MELD scores in PBC patients.This therapy revealed a trend of improvement in 3-,6-,or 12-month survival outcomes.
